Ulcerative Colitis

In the U.S., REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA.

REMICADE is the only biologic indicated for the treatment of patients with moderately-to-severely active CD who have had an inadequate response to conventional therapy.

REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing CD.

In December 2004, REMICADE was approved for reducing signs and symptoms in patients with active AS.

In May 2005, REMICADE was approved for reducing signs and symptoms of active arthritis in patients with PsA.

Additionally, in September 2005, REMICADE was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately-to-severely active UC who have had an inadequate response to conventional therapy.

This approval makes REMICADE the first and only biologic approved for the treatment of moderate to severe UC.

REMICADE is unique among available anti-TNF biologic therapies.

Unlike self-admin...

In the U.S., REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA.

REMICADE is the only biologic indicated for the treatment of patients with moderately-to-severely active CD who have had an inadequate response to conventional therapy.

REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing CD.

In December 2004, REMICADE was approved for reducing signs and symptoms in patients with active AS.

In May 2005, REMICADE was approved for reducing signs and symptoms of active arthritis in patients with PsA.

Additionally, in September 2005, REMICADE was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.

This approval makes REMICADE the first and only biologic approved for the treatment of moderate to severe UC.

REMICADE is unique among available anti-TNF biologic therapies.

Unlike self-a...

Brian Piper (North America), +1-484-595-8252.

Media,Jessica Mann (Rest of the World), +44-1256-894-280; Matthew Cabrey (NorthAmerica), +1-484-595-8248 Ticker Symbol: (NASDAQ-NMS:SHPGY),(Toronto:SHQ.) Terms and conditions of use applyCopyright © 2006 PR Newswire Association LLC.

All rights reserved.A United Business Media Company Printer Friendly Version Forward to a Friend Get Instant Access to our News Archive For more than 20 years, executives like you have relied on Engel Publishing Partners for the business, marketing, and clinical research information needed to make informed business decisions.

InfoPass gives you access to an array of integrated information services – information that is critical to your success and the success of ...